OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
OutSmart Cancer is the podcast for people who refuse to settle for one-size-fits-all cancer care. Hosted by Dr. Dino Prato, founder of Envita Medical Centers, this show offers expert insight into the world of precision oncology, integrative treatments, and the hidden factors that make cancer so hard to treat — and what to do about them.
For the last 25 years, Dr. Prato and his team have helped thousands of patients that have failed the largest hospitals utilizing the techniques and technology discussed in this series. Whether you’ve been newly diagnosed, are navigating treatment resistance, or want a second opinion grounded in science and compassion, you’ll hear empowering discussions on: DNA, RNA, and immune-based targeting, the truth behind standard protocols, what most doctors miss in treatment planning, stories of hope from patients who’ve been told “there’s nothing more we can do”
We believe in personalized, data-driven medicine — not protocol-based guessing.
You don’t have to fight cancer blindly. You can OutSmart it.
Disclaimer: This podcast is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before making medical decisions. Results vary and no specific outcomes are guaranteed. Some treatments may not be FDA-approved or available in all locations. Testimonials reflect individual experiences and may not represent typical outcomes. Certain therapies may be offered only at Envita’s international clinic in Hermosillo, Mexico.
OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
Insulin Peptide Cancer Treatment IPT: Truth vs Fiction
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
What if the goal of cancer treatment wasn’t more drug — but smarter delivery?
In this episode of Outsmart Cancer, Dr. Dino Prato explains how peptides and metabolic primers can dramatically improve the effectiveness of precision oncology when used correctly. Drawing from more than 25 years of clinical experience, Dr. Prato walks through the evolution from early insulin potentiation therapy (IPT) to today’s genetically targeted fractionated chemotherapy (GTFC) — a data-driven, immune-centric approach built on deep molecular mapping.
You’ll learn why insulin is not a treatment on its own, but a primer that can temporarily increase tumor uptake of microdosed chemotherapy — only when specific biomarkers are present. Dr. Prato explains how most chemotherapy misses the tumor entirely, and how metabolic primers like insulin, fasting windows, oxygenation, and redox modulation can shift that equation while protecting the immune system.
This episode breaks down how DNA sequencing, RNA transcriptomics, immune profiling, and spatial biology are used to select the right drugs first — and only then decide whether a primer like insulin makes sense. When combined correctly, this strategy promotes immunogenic cell death (DAMPS), trains dendritic cells and NK cells, and supports long-term immune control rather than short-term tumor suppression.
This is not alternative therapy. It’s precision delivery, immune intelligence, and metabolic strategy working together.
🎯 What You’ll Learn in This Episode:
• Why insulin is a peptide primer — not a cancer treatment
• How early insulin potentiation evolved into modern GTFC
• Why most chemotherapy never reaches the tumor
• How fasting and metabolic preparation improve drug tolerance
• What DAMPS are and why immune signaling determines long-term outcomes
• When insulin, oxygen, or inflammatory primers are appropriate — and when they’re not
• Why deep DNA, RNA, and immune mapping must come first
• How microdosed therapy strengthens immunity instead of destroying it
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576
“Precision isn’t about adding more — it’s about delivering smarter.”
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at:
https://www.scirp.org/journal/paperinformation?paperid=132493